Roche has injected funding into Palladio, creators of a drug for autosomal dominant polycystic kidney disease.
US-based kidney disease drug developer Palladio Biosciences closed a $20m series B round on Friday backed by pharmaceutical firm Roche through its corporate venturing unit, Roche Venture Fund.
Samsara BioCapital led the round, which also spinout-focused investment firm Osage University Partners and corporate-backed venture firm Medicxi.
Founded in 2015, Palladio Biosciences is progressing a clinical-stage drug called lixivaptan for autosomal dominant polycystic kidney disease (ADPKD), an inherited cause of kidney failure symptomised by the appearance of fluid-filled cysts.
The…
